Medtronic plc
NYSE:MDTMedical - Devices
+$0.75 today
- Market cap
- $128.84B
- Beta
- 0.60
- P/E (TTM)
- 21.1
- EPS (TTM)
- $3.74
- Dividend yield
- 3.60%
Volume 6.47M
Average 11.36M
MDT Pre-Tax Margin
Income before tax as a percentage of revenue.
Medtronic plcNYSE: MDT
Pre-Tax Margin · Q1 FY2027 · quarter ended Jul 2026
Pre-tax margin widens to 18.1%
Pre-tax margin was 18.1% in Q1 FY2027, up 3.0 pp from a year earlier. On a trailing-twelve-month basis it was 17.6%, up 1.0 pp year over year. Over 3 fiscal years it narrowed by 0.3 pp.
Context
- Pre-tax margin widened in 2 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Pre-Tax Margin history
Percent of revenue · from the income statement
- Latest · FY2026
- 16.9%
- Year-over-year change
- +0.1pp
| Period | Period end | Pre-Tax Margin | YoY change |
|---|---|---|---|
| FY2026 | 2026-04-24 | 16.9% | +0.1pp |
| FY2025 | 2025-04-25 | 16.8% | +1.8pp |
| FY2024 | 2024-04-26 | 14.9% | -2.2pp |
| FY2023 | 2023-04-28 | 17.2% | -0.2pp |
| FY2022 | 2022-04-29 | 17.4% | — |
Pre-Tax Margin vs competitors
How MDT compares with its peers on the latest reported figures
- MDT's LTM Jul 2026 pre-tax margin of 17.6% is the 4th highest of the 9 companies compared; the peer median is 12.3%.
- Its year-over-year change of +1.0 pp is the 5th highest of 9, against a peer median of +1.1 pp.
- Over three fiscal years its change of -0.3 pp compares with a peer median of +3.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 21.8% | -6.9 pp | -11.9 pp | |
| LTM Jun 2026 | 19.9% | +5.9 pp | +3.4 pp | |
| LTM Jun 2026 | 18.4% | +2.2 pp | +7.9 pp | |
| LTM Jul 2026 | 17.6% | +1.0 pp | -0.3 pp | |
| LTM Jun 2026 | 13.5% | +0.0 pp | +14.2 pp | |
| LTM Jun 2026 | 11.0% | -1.4 pp | +4.3 pp | |
| LTM Jun 2026 | 8.4% | +3.9 pp | +16.3 pp | |
| LTM Sep 2026 | 7.9% | +22.2 pp | -8.5 pp | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | -5116.2% | -1836.7 pp | -3970.6 pp |
| Peer median (excluding MDT) | 12.3% | +1.1 pp | +3.9 pp | |
Competitors are the stored peer set for MDT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Apr 2022 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 | FY2026 Apr 2026 |
|---|---|---|---|---|---|
| Revenue | 31.69B | 31.23B | 32.36B | 33.54B | 36.36B |
| Cost of Revenue | 10.15B | 10.72B | 11.22B | 11.63B | 12.72B |
| Gross Profit | 21.54B | 20.51B | 21.15B | 21.91B | 23.64B |
| Gross Margin | 68.0% | 65.7% | 65.3% | 65.3% | 65.0% |
| Research & Development | 2.75B | 2.7B | 2.74B | 2.73B | 2.87B |
| Selling, General & Admin | 10.29B | 10.42B | 10.74B | 10.85B | 11.78B |
| Operating Expenses | 15.79B | 15.02B | 16B | 15.95B | 17.18B |
| Depreciation & Amortization | 2.71B | 2.7B | 2.65B | 2.86B | 2.96B |
| EBITDA | 8.78B | 8.7B | 8.2B | 9.22B | 9.81B |
| EBITDA Margin | 27.7% | 27.9% | 25.3% | 27.5% | 27.0% |
| Operating Income | 5.75B | 5.49B | 5.14B | 5.96B | 6.47B |
| Operating Margin | 18.2% | 17.6% | 15.9% | 17.8% | 17.8% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 553M | 636M | 719M | 729M | 715M |
| Other Income / Expenses | (235M) | (121M) | (307M) | (327M) | (331M) |
| Income Before Tax | 5.52B | 5.36B | 4.84B | 5.63B | 6.14B |
| Pre-Tax Margin | 17.4% | 17.2% | 14.9% | 16.8% | 16.9% |
| Income Tax Expense | 456M | 1.58B | 1.13B | 936M | 1.3B |
| Net Income | 5.04B | 3.76B | 3.68B | 4.66B | 4.8B |
| Net Margin | 15.9% | 12.0% | 11.4% | 13.9% | 13.2% |
| EPS (Basic) | 3.75 | 2.83 | 2.77 | 3.63 | 3.75 |
| EPS (Diluted) | 3.73 | 2.82 | 2.76 | 3.61 | 3.73 |
| Weighted Avg Shares | 1.34B | 1.33B | 1.33B | 1.29B | 1.28B |
| Weighted Avg Shares (Diluted) | 1.35B | 1.33B | 1.33B | 1.29B | 1.29B |
Medtronic plc
NYSE:MDT
Intrinsic Alpha fair value
Locked
Current Price
$100.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.